Parathyroid carcinoma: the decisions you may face

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

1. Which specific treatments are you proposing for this setting, and what are the alternatives?
   Why: The standard of care here is described in words rather than named products; ask for the names.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. Does your recommendation follow the current guideline (NCCN Neuroendocrine and Adrenal Tumors (parathyroid carcinoma); American Association of Endocrine Surgeons guideline 2016), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
5. For my situation (suspected or confirmed carcinoma, resectable), which of the standard options do you recommend and why?
   Why: Guideline options include: En bloc resection with ipsilateral thyroid lobectomy and removal of adherent tissue, avoiding capsule rupture; re-resection for loco-regional recurrence.

Add these to your appointment list, or take the full question set for this cancer.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

1. Between Bone-modifying agents (bisphosphonates, denosumab) and Cinacalcet, which do you recommend for me, and what about my case would make you choose differently?
   Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. Does your recommendation follow the current guideline (NCCN Neuroendocrine and Adrenal Tumors), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
5. For my situation (hypercalcaemia, unresectable or metastatic disease), which of the standard options do you recommend and why?
   Why: Guideline options include: Cinacalcet titrated to calcium, denosumab or intravenous bisphosphonate, hydration; palliative resection or ablation of metastases to reduce PTH burden.
6. Am I a candidate for Cinacalcet, and what side effects should I expect?
   Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

1. Is Germline (hereditary) testing the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
   Why: A single standard does not mean a single choice; timing and trials are decisions too.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. For my situation (all patients), which of the standard options do you recommend and why?
   Why: Guideline options include: Germline CDC73 testing and family counselling; surveillance for jaw and renal tumours in carriers.

Add these to your appointment list, or take the full question set for this cancer.